EP3529263A4 - Molécules multimériques à base d'il-15 - Google Patents

Molécules multimériques à base d'il-15 Download PDF

Info

Publication number
EP3529263A4
EP3529263A4 EP17861811.2A EP17861811A EP3529263A4 EP 3529263 A4 EP3529263 A4 EP 3529263A4 EP 17861811 A EP17861811 A EP 17861811A EP 3529263 A4 EP3529263 A4 EP 3529263A4
Authority
EP
European Patent Office
Prior art keywords
multimers
based molecules
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP17861811.2A
Other languages
German (de)
English (en)
Other versions
EP3529263B1 (fr
EP3529263A1 (fr
Inventor
Hing C. Wong
Warren MARCUS
Bai LIU
Wenxin Xu
Robby NEWMAN
Karen Kage
Lijing YOU
Peter Rhode
Patrick Soon-Shiong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altor Bioscience LLC
Immunitybio Inc
Original Assignee
Altor Bioscience LLC
NantCell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altor Bioscience LLC, NantCell Inc filed Critical Altor Bioscience LLC
Priority to EP25187905.2A priority Critical patent/EP4613776A3/fr
Publication of EP3529263A1 publication Critical patent/EP3529263A1/fr
Publication of EP3529263A4 publication Critical patent/EP3529263A4/fr
Application granted granted Critical
Publication of EP3529263B1 publication Critical patent/EP3529263B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP17861811.2A 2016-10-21 2017-10-21 Molécules multimériques à base d'il-15 Active EP3529263B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP25187905.2A EP4613776A3 (fr) 2016-10-21 2017-10-21 Molécules multimériques à base d'il-15

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662411216P 2016-10-21 2016-10-21
US201762513964P 2017-06-01 2017-06-01
PCT/US2017/057757 WO2018075989A1 (fr) 2016-10-21 2017-10-21 Molécules multimériques à base d'il-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP25187905.2A Division EP4613776A3 (fr) 2016-10-21 2017-10-21 Molécules multimériques à base d'il-15

Publications (3)

Publication Number Publication Date
EP3529263A1 EP3529263A1 (fr) 2019-08-28
EP3529263A4 true EP3529263A4 (fr) 2020-07-08
EP3529263B1 EP3529263B1 (fr) 2025-08-06

Family

ID=62019612

Family Applications (2)

Application Number Title Priority Date Filing Date
EP25187905.2A Pending EP4613776A3 (fr) 2016-10-21 2017-10-21 Molécules multimériques à base d'il-15
EP17861811.2A Active EP3529263B1 (fr) 2016-10-21 2017-10-21 Molécules multimériques à base d'il-15

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP25187905.2A Pending EP4613776A3 (fr) 2016-10-21 2017-10-21 Molécules multimériques à base d'il-15

Country Status (12)

Country Link
US (3) US20180200366A1 (fr)
EP (2) EP4613776A3 (fr)
JP (1) JP7492336B2 (fr)
KR (2) KR20190091264A (fr)
CN (2) CN118562016A (fr)
AU (1) AU2017345791B2 (fr)
BR (1) BR112019007920A2 (fr)
CA (2) CA3200275A1 (fr)
IL (1) IL266100B2 (fr)
MX (1) MX2019004681A (fr)
SG (1) SG11201903306SA (fr)
WO (1) WO2018075989A1 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743249B (zh) 2007-05-11 2017-08-08 阿尔托生物科学有限公司 融合分子与il‑15变异体
KR102762243B1 (ko) 2014-06-30 2025-02-05 알토 바이오사이언스 엘엘씨 Il-15-베이즈드 분자 및 이의 사용 방법
JP2019519516A (ja) 2016-05-18 2019-07-11 モデルナティーエックス， インコーポレイテッド がんの治療のためのｍＲＮＡ併用療法
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
MY203000A (en) 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
EP4613776A3 (fr) 2016-10-21 2025-11-26 Altor BioScience Corporation Molécules multimériques à base d'il-15
KR102867975B1 (ko) 2017-03-06 2025-10-14 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
KR102698752B1 (ko) * 2017-03-20 2024-08-26 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
WO2019006472A1 (fr) 2017-06-30 2019-01-03 Xencor, Inc. Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
JP2020533971A (ja) 2017-08-28 2020-11-26 アルター・バイオサイエンス・コーポレーション Ｉｌ−１５をベースとするｉｌ−７及びｉｌ−２１への融合物
CA3074826A1 (fr) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Compositions proteiques therapeutiques et procedes de preparation et d'utilisation de celles-ci
EA202092044A1 (ru) * 2018-03-14 2021-03-03 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные рецепторы антигена против cd33 и их применения
MA52289A (fr) 2018-04-18 2021-02-24 Xencor Inc Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
EP3781598A1 (fr) 2018-04-18 2021-02-24 Xencor, Inc. Protéines de fusion hétérodimères ciblant tim-3 contenant des protéines de fusion fc d'il-15/il-15ra et domaines de liaison à l'antigène de tim-3
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
WO2019204646A1 (fr) 2018-04-18 2019-10-24 Xencor, Inc. Protéines de fusion hétérodimères ciblant lag-3 contenant des protéines de fusion fc d'il-15/il-15ra et domaines de liaison à l'antigène de lag-3
MX2020013621A (es) 2018-06-19 2021-03-25 Nantcell Inc Composiciones y metodos de tratamiento de vih.
WO2020023713A1 (fr) * 2018-07-26 2020-01-30 Nantbio, Inc. Compositions et procédés de tri-cytokine txm
CN120365435A (zh) * 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
EP3843788A1 (fr) 2018-08-30 2021-07-07 HCW Biologics, Inc. Polypeptides chimériques à chaîne unique et leurs utilisations
CN112996805A (zh) * 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
EP3847242A4 (fr) 2018-09-07 2022-06-08 NantBio, Inc. Traitements ciblés à base d'il-12 et méthodes de stimulation des cellules hank et nk92mi
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
AU2019359475A1 (en) 2018-10-12 2021-05-20 Xencor, Inc. PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
KR102533540B1 (ko) 2018-10-31 2023-05-17 난트퀘스트, 인크. Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거(elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells)
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
AU2020206269A1 (en) * 2019-01-11 2021-08-05 Memorial Sloan Kettering Cancer Center Multimerization of IL-15/IL-15R-alpha-Fc complexes to enhance immunotherapy
CN114040978B (zh) * 2019-05-31 2025-10-17 希望之城公司 用于治疗cd33阳性恶性肿瘤的经cd33靶向性嵌合抗原受体修饰的t细胞
JP7713393B2 (ja) 2019-06-21 2025-07-25 イミュニティーバイオ インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
US20220289838A1 (en) * 2019-08-19 2022-09-15 Nantong Yichen Biopharma. Co. Ltd. Immunocytokine, Preparation for the Same, and Uses Thereof
US20210061871A1 (en) * 2019-08-29 2021-03-04 Nantbio, Inc. Modified N-810 and Methods Therefor
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
EP4041757A4 (fr) * 2019-09-26 2024-04-17 Regents of the University of Minnesota Composés d'engagement de cellules nk qui se lient à des antigènes viraux et procédés d'utilisation
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
JP2023502712A (ja) * 2019-11-21 2023-01-25 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法
US20210188933A1 (en) * 2019-12-18 2021-06-24 Nantcell, Inc Methods of treating pancytopenia
US20210244821A1 (en) * 2020-02-05 2021-08-12 Novartis Ag Cho cell expressed het il-15
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
EP4103599A1 (fr) 2020-02-11 2022-12-21 HCW Biologics, Inc. Méthodes d'activation de lymphocytes t régulateurs
US12115191B2 (en) 2020-02-11 2024-10-15 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
EP4143231A1 (fr) 2020-04-29 2023-03-08 HCW Biologics, Inc. Protéines anti-cd26 et leurs utilisations
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
JP2023532279A (ja) * 2020-06-26 2023-07-27 ソレント・セラピューティクス・インコーポレイテッド 免疫調節性融合タンパク質を発現する腫瘍溶解性単純ヘルペスウイルス（ｈｓｖ）
US12006507B2 (en) 2020-07-22 2024-06-11 Nantcell, Inc. Electroporation with active compensation
KR102863510B1 (ko) * 2020-08-03 2025-09-23 난트셀, 인크. Il-15 초작용제에 대한 약물-특이적 약동학 검정 (drug-specific pharmacokinetic assay for il-15 superagonist cross-reference to related applications)
WO2022042576A1 (fr) * 2020-08-27 2022-03-03 盛禾(中国)生物制药有限公司 Protéine de fusion multifonctionnelle et son utilisation
WO2022090203A1 (fr) * 2020-10-26 2022-05-05 Cytune Pharma AGONISTE IL-2/IL-15RβҮ POUR TRAITER LE CARCINOME MALPIGHIEN
EP4232068A1 (fr) * 2020-10-26 2023-08-30 Cytune Pharma Agoniste d'il-2/il-15r?? pour le traitement du cancer de la peau non mélanome
WO2022140701A1 (fr) * 2020-12-24 2022-06-30 Xencor, Inc. Protéines de fusion hétérodimères ciblées par icos contenant des protéines de fusion fc d'il-15/il-15ra et domaines de liaison à l'antigène icos
CN112795543B (zh) * 2021-02-04 2022-09-27 华中农业大学 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用
JP2024506292A (ja) * 2021-02-05 2024-02-13 サルブリス バイオセラピューティクス，インコーポレイティド Ｉｌ－１５融合タンパク質と、その製造法ならびに利用法
CN114917329B (zh) * 2021-02-11 2023-07-21 兰州大学第二医院 抗cd87抗体与抗pd1抗体联合治疗胃癌
CN113106068A (zh) * 2021-03-26 2021-07-13 深圳市先康达生命科学有限公司 一种自分泌IL-15与anti-PD1融合蛋白的免疫细胞
WO2022260849A1 (fr) 2021-06-09 2022-12-15 Nant Holdings Ip, Llc Procédés et systèmes de production d'une protéine d'intérêt dans une plante
WO2023049832A1 (fr) * 2021-09-23 2023-03-30 Sagittarius Bio, Inc. Polypeptides d'il-12 et il-15
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
EP4507711A1 (fr) 2022-04-13 2025-02-19 ImmunityBio, Inc. Polypeptide chimérique à chaînes multiples destiné à être utilisé dans le traitement d'un trouble neuro-inflammatoire
CN116217735A (zh) * 2022-08-03 2023-06-06 深圳市先康达生命科学有限公司 一种自分泌IL-15与anti-TIM3结合的融合蛋白及其应用
CN115806628A (zh) * 2022-08-03 2023-03-17 深圳市先康达生命科学有限公司 一种自分泌IL-15与anti-TIGIT结合的融合蛋白及其应用
CN115806629A (zh) * 2022-08-03 2023-03-17 深圳市先康达生命科学有限公司 一种自分泌IL-15与anti-CTLA4结合的融合蛋白及其应用
WO2024102636A1 (fr) 2022-11-07 2024-05-16 Xencor, Inc. Anticorps bispécifiques qui se lient à b7h3 et mica/b
CN116789837B (zh) * 2023-03-24 2024-02-23 山西纳安生物科技股份有限公司 一种抗组织因子人源化抗体及制备的抗体偶联药物和应用
CN116574192A (zh) * 2023-03-30 2023-08-11 上海妙聚生物科技有限公司 一种可条件性释放并激活的细胞因子融合蛋白及其制备和用途
WO2024263698A1 (fr) * 2023-06-22 2024-12-26 Memorial Sloan-Kettering Cancer Center Compositions associées à l'immunoglobuline anti-pd-l1 comprenant des polypeptides de fusion il-15-il-15ra et leurs utilisations
WO2025085672A1 (fr) 2023-10-17 2025-04-24 Xencor, Inc. Anticorps bispécifiques qui se lient à nkp46 et mica/b
WO2025119308A1 (fr) * 2023-12-08 2025-06-12 百奥泰生物制药股份有限公司 Protéine de fusion et son utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143794A1 (fr) * 2007-05-11 2008-11-27 Altor Bioscience Corporation Molécules de fusion et variantes de il-15
WO2015109124A2 (fr) * 2014-01-15 2015-07-23 Kadmon Corporation, Llc Agents immunomodulateurs

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1975A (en) 1841-02-12 Manner of constructing corn-shellers
JPS5291285A (en) 1976-01-23 1977-08-01 Hitachi Ltd Escalator
JPS5841623B2 (ja) 1978-12-25 1983-09-13 株式会社東芝 質量分析装置のイオン検出器
JPS5718916A (en) 1980-07-11 1982-01-30 Iseki Agricult Mach Shaking table sorter of automatic feeding type thresher
JPS5770185A (en) 1980-10-21 1982-04-30 Kazuo Makino Preparation of blended oil for coal liquefaction
JPS57144287A (en) 1981-03-02 1982-09-06 Toray Ind Inc Cyclopentabenzofuran derivative
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU5098393A (en) 1992-08-14 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
AU680909B2 (en) 1994-04-06 1997-08-14 Immunex Corporation Interleukin-15
WO1995027722A1 (fr) 1994-04-06 1995-10-19 Immunex Corporation Interleukine-15
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1997041232A1 (fr) 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center Antagonistes de l'interleukine-15
ATE229342T1 (de) 1997-02-21 2002-12-15 Vlaams Interuniv Inst Biotech Verwendung von interleukin-15
EP1284747A2 (fr) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions et procedes pour obtenir une suppression immune
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
EP1349873B1 (fr) 2000-09-14 2009-04-01 Beth Israel Deaconess Medical Center, Inc. Modulation de reactions de cellules t induites par il-15 et il-2
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
WO2004028339A2 (fr) 2002-09-27 2004-04-08 Brigham And Women's Hospital, Inc. Traitement de patients atteints de sclerose en plaques base sur des modifications de l'expression genetique dans des tissus du systeme nerveux central
JP4892335B2 (ja) 2003-02-26 2012-03-07 ゲンマブ エー／エス インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体
DE10324708A1 (de) 2003-05-30 2004-12-16 Ltn Servotechnik Gmbh Schleifringelement und Verfahren zu dessen Herstellung
CN1233822C (zh) 2003-09-05 2005-12-28 中国科学技术大学 白细胞介素－15基因修饰的自然杀伤细胞株及其制备方法
KR101131297B1 (ko) 2003-11-10 2012-03-30 알토 바이오사이언스 코포레이션 가용성 티씨알 분자 및 이용 방법
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
EP1586585A1 (fr) 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Système d'expression pour la production des protéines de fusion IL-15/Fc et leur utilisation
CN100334112C (zh) 2004-10-15 2007-08-29 上海海欣生物技术有限公司 人白细胞介素15与Fc融合蛋白
EP1814580B1 (fr) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methodes d'utilisation d'il-21 pour l'immunotherapie adoptive et l'identification d'antigenes tumoraux
WO2006063974A2 (fr) 2004-12-13 2006-06-22 Cytos Biotechnology Ag Jeux ordonnes d'antigenes il-15 et leurs utilisations
EP3263581B2 (fr) 2005-05-17 2025-07-09 University of Connecticut Compositions et procédés d'immunomodulation dans un organisme
EP1777294A1 (fr) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion
ES2352561T3 (es) 2006-06-30 2011-02-21 Conaris Research Institute Ag Dímeros de sgp 130fc mejorados.
US7965180B2 (en) 2006-09-28 2011-06-21 Semiconductor Energy Laboratory Co., Ltd. Wireless sensor device
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
AU2013273643C1 (en) 2007-05-11 2016-08-11 Altor Bioscience Corporation Fusion molecules and il-15 variants
AU2008279550B2 (en) 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
NZ599338A (en) 2007-06-27 2013-11-29 Marinepolymer Tech Inc Complexes of il-15 and il-15ralpha and uses thereof
US7837588B2 (en) 2007-07-20 2010-11-23 American Axle & Manufacturing, Inc. Pre-load mechanism for helical gear differential
US20110070191A1 (en) 2008-03-19 2011-03-24 Wong Hing C T cell receptor fusions and conjugates and methods of use there of
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
US8507222B2 (en) 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
EP2537933A1 (fr) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
WO2013163427A1 (fr) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps pour traiter les infections par le vih-1
WO2013189901A1 (fr) 2012-06-18 2013-12-27 Novartis Ag Gp120 stabilisée
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014028776A1 (fr) 2012-08-15 2014-02-20 Zyngenia, Inc. Complexes multispécifiques monovalents et multivalents et leurs utilisations
CN118955699A (zh) 2012-10-18 2024-11-15 洛克菲勒大学 广泛中和性抗hiv抗体
US20150359853A1 (en) 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
KR102762243B1 (ko) 2014-06-30 2025-02-05 알토 바이오사이언스 엘엘씨 Il-15-베이즈드 분자 및 이의 사용 방법
CN104672325A (zh) 2015-03-11 2015-06-03 福建农林大学 一种用新鲜螺旋藻制备藻蓝蛋白的方法
ES2789348T3 (es) 2015-03-20 2020-10-26 Us Health Anticuerpos neutralizantes para GP120 y sus usos
JP2018532729A (ja) 2015-09-25 2018-11-08 アルター・バイオサイエンス・コーポレーション インターロイキン−１５スーパーアゴニストは、移植片対腫瘍活性を大幅に増強する
US10865230B2 (en) 2016-05-27 2020-12-15 Altor Bioscience, Llc Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
EP4613776A3 (fr) 2016-10-21 2025-11-26 Altor BioScience Corporation Molécules multimériques à base d'il-15
US11168138B2 (en) 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143794A1 (fr) * 2007-05-11 2008-11-27 Altor Bioscience Corporation Molécules de fusion et variantes de il-15
WO2015109124A2 (fr) * 2014-01-15 2015-07-23 Kadmon Corporation, Llc Agents immunomodulateurs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAI LIU ET AL: "A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 291, no. 46, 20 September 2016 (2016-09-20), US, pages 23869 - 23881, XP055566201, ISSN: 0021-9258, DOI: 10.1074/jbc.M116.733600 *
FELICES M ET AL: "IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer", GYNECOLOGIC ONCOLOGY, vol. 145, no. 3, 22 February 2017 (2017-02-22), pages 453 - 461, XP085039603, ISSN: 0090-8258, DOI: 10.1016/J.YGYNO.2017.02.028 *
See also references of WO2018075989A1 *

Also Published As

Publication number Publication date
EP3529263B1 (fr) 2025-08-06
JP7492336B2 (ja) 2024-05-29
US20180200366A1 (en) 2018-07-19
KR20210062749A (ko) 2021-05-31
US20200261575A1 (en) 2020-08-20
US11318201B2 (en) 2022-05-03
EP4613776A2 (fr) 2025-09-10
IL266100B2 (en) 2023-02-01
CA3041310C (fr) 2023-09-05
EP4613776A3 (fr) 2025-11-26
JP2019533449A (ja) 2019-11-21
IL266100A (en) 2019-06-30
US11369679B2 (en) 2022-06-28
CN118562016A (zh) 2024-08-30
SG11201903306SA (en) 2019-05-30
CA3200275A1 (fr) 2018-04-26
KR20190091264A (ko) 2019-08-05
WO2018075989A1 (fr) 2018-04-26
MX2019004681A (es) 2019-10-07
US20210196821A1 (en) 2021-07-01
CN110799528B (zh) 2024-06-14
CN110799528A (zh) 2020-02-14
EP3529263A1 (fr) 2019-08-28
KR102392142B1 (ko) 2022-04-28
AU2017345791A1 (en) 2019-05-09
CA3041310A1 (fr) 2018-04-26
AU2017345791B2 (en) 2020-10-22
BR112019007920A2 (pt) 2019-10-08
IL266100B (en) 2022-10-01

Similar Documents

Publication Publication Date Title
EP3529263A4 (fr) Molécules multimériques à base d'il-15
EP3529529C0 (fr) Système de support d'écran
EP4226898C0 (fr) Unité actionneur-amortisseur
EP3402944C0 (fr) Étançon
EP3382683A4 (fr) Afficheur
DK3330593T3 (da) Halo-lysenhed
EP3219592C0 (fr) Fixation
DK3242685T3 (da) Cxcr4-bindende molekyler
BR112016016826A2 (pt) suporte flexível
FR3022127B3 (fr) Support auxiliaire
EP4146905C0 (fr) Ensemble diffuseur
IL249254A0 (en) Gene expression system
DE112015002689A5 (de) Lüfteranordnung
DK3606953T3 (da) Fgfr3-bindende molekyler
DK3182940T3 (da) Støttestruktur
DK3193674T3 (da) Monteringsenhed
EP3561320A4 (fr) Dispositif de retenue
DE102015110622A8 (de) Erinnerungen basierend auf virtuellen Standorten
DE112014006652A5 (de) Lenkeinschlagunterstützung
DE112015001852A5 (de) Gehäuseanordnung
EP3402688A4 (fr) Pare-soleil
EP3501021A4 (fr) Écran
DE112015000374A5 (de) Trägereinrichtung
DE112017001443A5 (de) Stütze
DE112017004607T8 (de) Nabeneinheit

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190514

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LIU, BAI

Inventor name: SOON-SHIONG, PATRICK

Inventor name: XU, WENXIN

Inventor name: MARCUS, WARREN

Inventor name: YOU, LIJING

Inventor name: KAGE, KAREN

Inventor name: RHODE, PETER

Inventor name: NEWMAN, ROBBY

Inventor name: WONG, HING, C.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200608

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/705 20060101ALI20200602BHEP

Ipc: C07K 16/30 20060101ALI20200602BHEP

Ipc: C07K 14/715 20060101ALI20200602BHEP

Ipc: C07K 14/54 20060101AFI20200602BHEP

Ipc: C07K 16/24 20060101ALI20200602BHEP

Ipc: C07K 14/47 20060101ALI20200602BHEP

Ipc: A61P 31/18 20060101ALI20200602BHEP

Ipc: C07K 16/32 20060101ALI20200602BHEP

Ipc: C07K 16/18 20060101ALI20200602BHEP

Ipc: C07K 14/435 20060101ALI20200602BHEP

Ipc: C07K 16/36 20060101ALI20200602BHEP

Ipc: A61K 38/00 20060101ALI20200602BHEP

Ipc: C07K 16/10 20060101ALI20200602BHEP

Ipc: A61P 35/00 20060101ALI20200602BHEP

Ipc: C07K 16/28 20060101ALI20200602BHEP

Ipc: A61K 39/00 20060101ALI20200602BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40014316

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210805

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230529

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20250224

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SOON-SHIONG, PATRICK

Inventor name: RHODE, PETER

Inventor name: YOU, LIJING

Inventor name: KAGE, KAREN

Inventor name: NEWMAN, ROBBY

Inventor name: XU, WENXIN

Inventor name: LIU, BAI

Inventor name: MARCUS, WARREN

Inventor name: WONG, HING, C.

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SOON-SHIONG, PATRICK

Inventor name: RHODE, PETER

Inventor name: YOU, LIJING

Inventor name: KAGE, KAREN

Inventor name: NEWMAN, ROBBY

Inventor name: XU, WENXIN

Inventor name: LIU, BAI

Inventor name: MARCUS, WARREN

Inventor name: WONG, HING, C.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WONG, HING, C.

Inventor name: MARCUS, WARREN

Inventor name: LIU, BAI

Inventor name: XU, WENXIN

Inventor name: NEWMAN, ROBERT G.

Inventor name: KAGE, KAREN

Inventor name: YOU, LIJING

Inventor name: RHODE, PETER

Inventor name: SOON-SHIONG, PATRICK

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017091078

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20250806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251206

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20251021

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251022

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251106

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20251030

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1821749

Country of ref document: AT

Kind code of ref document: T

Effective date: 20250806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250806